Showing results (461-470 of 577) with videos related to

Sort By:
Pageof 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
The Lancet. Oncology|April 11, 2014
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trialJohn Primrose, Stephen Falk, Meg Finch-Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal CancerShelize Khakoo, Paul David Carter, Gina Brown, et al.
Circulation|February 1, 2015
Transcatheter aortic valve implantation in the United Kingdom: temporal trends, predictors of outcome, and 6-year follow-up: a report from the UK Transcatheter Aortic Valve Implantation (TAVI) Registry, 2007 to 2012Peter F Ludman, Neil Moat, Mark A de Belder, et al.
International Journal of Hematology|November 19, 2021
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trialGrzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, et al.
Scientific Reports|May 23, 2019
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular SubtypesChanthirika Ragulan, Katherine Eason, Elisa Fontana, et al.
The Lancet. Gastroenterology & Hepatology|June 27, 2017
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trialTim Meyer, Richard Fox, Yuk Ting Ma, et al.
JCO Oncology Advances|May 7, 2025
Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM StudyAnderley Gordon, David Cunningham, Zayn Rajan, et al.
Leukemia & Lymphoma|November 10, 2017
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie HospitalMary Gleeson, Clare Peckitt, David Cunningham, et al.
Pageof 58